.svg)
You are now leaving Astellas.us. The website you are linking to is neither owned nor controlled by Astellas.
Astellas is not responsible for the content or services on this site.
News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Oct 1, 2019Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene TherapyFinancial Support for LabCentral Incubators Builds on Astellas' $1 Billion+ Investment in Boston's Life Science Community
-
Sep 30, 2019- Finalists will present their ideas during a live pitch event
-
Sep 28, 2019- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -
Sep 24, 2019- Astellas named Working Mother "100 Best Company" for fifth consecutive year --
Sep 20, 2019If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)
Sep 18, 2019- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 --
Sep 16, 2019- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -
-
Sep 11, 2019Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas